Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient

Weijia Wang, Cynthia A. James, and Hugh Calkins*

Division of Cardiology, Department of Medicine, Johns Hopkins University, 600 N. Wolfe Street, Sheikh Zayed Tower 7125R, Baltimore, MD 21287, USA

Received 15 December 2017; editorial decision 11 March 2018; accepted 16 March 2018; online publish-ahead-of-print 23 April 2018

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare inherited heart muscle disease characterized by ventricular tachyarrhythmia, predominant right ventricular dysfunction, and sudden cardiac death. Its pathophysiology involves close interaction between genetic mutations and exposure to physical activity. Mutations in genes encoding desmosomal protein are the most common genetic basis. Genetic testing plays important roles in diagnosis and screening of family members. Syncope, palpitation, and lightheadedness are the most common symptoms. The 2010 Task Force Criteria is the standard for diagnosis today. Implantation of a defibrillator in high-risk patients is the only therapy that provides adequate protection against sudden death. Selection of patients who are best candidates for defibrillator implantation is challenging. Exercise restriction is critical in affected individuals and at-risk family members. Antiarrhythmic drugs and ventricular tachycardia ablation are valuable but palliative components of the management. This review focuses on the current diagnostic and therapeutic strategies in ARVD/C and outlines the future area of development in this field.

Keywords
Arrhythmogenic right ventricular dysplasia/cardiomyopathy • Genetic • Antiarrhythmic drugs • Implantable cardioverter-defibrillators • Ventricular tachycardia • Sudden cardiac death

Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart muscle disease characterized by ventricular arrhythmias, an increased risk of sudden death, and predominant right ventricular dysfunction.1 The pathological hallmark of ARVD/C is myocyte loss with fibro-fatty production. Since the first case series in 1982,2-4 our understanding of its pathogenesis, clinical manifestations, and long-term outcomes has advanced significantly. Arrhythmogenic right ventricular dysplasia/cardiomyopathy was initially considered to be a congenital defect in the right ventricular myocardium and designated as dysplasia but later was reclassified as a cardiomyopathy.5 While involvement of the right ventricle typically predominates in early disease, biventricular, and left dominant forms are now recognized to be an important part of the disease spectrum.6 The purpose of this review article is to provide an update concerning the diagnosis and treatment strategies in ARVD/C.

Epidemiology
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is a rare condition7 and has an estimated prevalence of 1:5000.8 Arrhythmogenic right ventricular dysplasia/cardiomyopathy patients typically present in the 2nd to 4th decade of life.9-11 Approximately 20% of the patients present after age of 50 years. Late presentation does not confer a benign prognosis.12 Men are more commonly affected with earlier onset than women and have worse outcomes once diagnosed.13-15 This may be explained by sex-related difference in hormone profiles and exercise participation.16,17

Genetic basis
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is mainly inherited in an autosomal-dominant pattern with incomplete...
penetrance and variable expressivity. Autosomal recessive forms have also been described and can be associated with wooly hair and palmoplantar keratoderma, such as in Naxos disease and Carvajal syndrome.

The discovery of the genetic basis of Naxos disease identified the first disease-causing gene in ARVD/C. It is located at chromosome 17q21 and encodes plakoglobin (JUP), a desmosomal protein important in cell-to-cell adhesion. This was followed by the discovery of mutations in genes that encode other desmosomal proteins including desmoplakin (DSP), plakoglobin-2 (PKP2), desmoglein-2 (DSG2), and desmocolin-2 (DSC2), all of which cause autosomal-dominant forms of ARVD/C.

Mutations in genes encoding non-desmosomal proteins have also been identified. Most are associated with other cardiomyopathies and arrhythmia syndrome and represent phenotypic overlap. These include the intermediate filament protein desmin (DES), the cardiac sodium channel—Na, 1.5 (SCN5A), lamin A/C (LMNA) on the nuclear membrane, titin (TTN), phospholamban (PLN), and filamin C (FLNC). Pathogenic variants in genes encoding proteins of the area composita, α-T-Catenin (CTNNA3), and N-cadherin (CDH2) have been identified in a small group of ARVD/C patients with typical right-predominant disease. The pS358L founder mutation in TMEM43, encoding transmembrane protein 43 is common among French Canadian ARVD/C patients. Possible mutations in transforming growth factor-beta-3 (TGFβ3) have been described but association with ARVD/C remains to be confirmed.

Among all the index cases, PKP2 is the most commonly mutated gene (20–46%), followed by DSP (3–15%), DSG2 (3–20%), DSC2 (1–8%), and JUP (<1%). Non-desmosomal genes account for less than 10% of all pathological variants.

Attempts have been made to correlate genotypes to phenotypes. Patients with more than 1 mutation (4–16%) have earlier disease onset and worse disease outcomes including arrhythmia, sudden cardiac death, and heart failure. As in Carvajal syndrome, DSP mutations are also associated with left ventricular dysfunction, sometimes referred to as arrhythmogenic left ventricular dysplasia, Table 1 provides a list of the genes for which ARVD/C-associated disease-causing mutations have been identified. Novel mutations can be found and registered at www.ARVD/Cdatabase.info.

### Pathophysiology

Arrhythmogenic right ventricular dysplasia/cardiomyopathy is hypothesized as a disease of desmosomal dysfunction based on its genetics. This is supported by the remodelling of intercalated disk and loss of desmosomes observed in ultrastructural studies. Desmosomes and gap junctions are responsible for maintaining cell adhesion, signal transduction, and electrical integrity, all of which have been implicated in the disease pathophysiology.

Defective desmosomal proteins lead to loss of adhesion between cardiac myocytes followed by inflammation, fibrosis, death, and production by fibrofatty tissue. This may be aggravated by wall stress from physical activity which disproportionately affects right ventricle compared with left ventricle.

Besides providing mechanical cell adhesion, desmosomes are also important in intracellular and intercellular signal transduction.

| Gene      | Protein encoded | % cases |
|-----------|----------------|--------|
| PKP2      | Plakophilin-2   | 20–46  |
| DSP       | Desmoplakin     | 3–15   |
| DSG2      | Desmoglein-2    | 3–20   |
| DSC2      | Desmocolin-2    | 1–8    |
| JUP       | Plakoglobin     | <1     |
| CTNNA3    | α-T-Catenin     | <2     |
| CDH2      | N-cadherin      | <2     |
| TMEM43    | Transmembrane protein 43 | <2 |
| LMNA      | Lamin A/C       | <4     |
| SCN5A     | Na, 1.5         | 2      |
| DES       | Desmin          | <2     |
| PLN       | Phospholamban   | <1     |
| TTN       | Titin           | <10    |

Desmosomal alteration redistributes plakoglobin from cell surface to cytosol and nucleus, which suppresses canonical Wnt signalling by competing with β-catenin. It promotes adipogenesis in the heart by increasing adipogenic factors and reducing inhibitors of adipogenesis, which may explain the typical fibroadipocytic production in ARVD/C. Lipogenesis and apoptosis have been reproduced by induction of adult-like metabolism in an in vitro model generated by patient-specific mutant PKP2 induced pluripotent stem cells-derived cardiomyocytes. Apart from protein relocation, epitope masking has also been reported to cause reduced plakoglobin immunoreactivity in intercalated discs.

Desmosomes also maintain electrical integrity by forming a coordinated protein network called ‘connexome’ at the intercalated disks by interacting with ion channels and gap junctions. Disruption of electrical coupling may explain the increased arrhythmia susceptibility in ARVD/C even before the onset of significant fibrosis and necrosis. The aggregation of voltage-gated sodium channels with cell adhesion molecules and reduced sodium current from desmosomal mutations may explain the phenotypic overlapping between ARVD/C and Brugada syndrome. Clinically, both conditions can manifest as right precordial electrocardiography (ECG) repolarization abnormalities, right ventricular outflow tract (RVOT) conduction disturbances, and ventricular arrhythmias the from right ventricle.

Pathologically, fatty infiltration of the myocardium has been reported in both conditions. As a result, ARVD/C and Brugada syndrome might be at the ends of a spectrum of structural myocardopathies and sodium current deficiency that share a common origin from abnormal connexome.

Exercise has been shown to exacerbate phenotypes in mice with ARVD/C associated mutations. In clinical studies, exercise is associated with disease penetrance and ventricular arrhythmia in ARVD/C. On a population level, ARVD/C has also been reported as a leading cause of sudden cardiac death in competitive athletes.
Clinical manifestations

The presentation of ARVD/C varies considerably, ranging from proband patients with symptoms related to arrhythmia and heart failure to asymptomatic family members diagnosed in the context of cascade screening. Based on experience from referral centres, index patients usually present with palpitations (30–60%), lightheadedness (20%), and syncope (10–30%). These symptoms are in turn linked to the presence of non-sustained or sustained ventricular arrhythmias. Up to 19% of ARVD/C patients present as cardiac arrest. Arrhythmogenic right ventricular dysplasia/cardiomyopathy can occasionally manifest as chest pain accompanied by transient ischaemic electrocardiographic changes and troponin elevation, mimicking acute myocarditis and heart attack. Atypical chest pain may be explained by small vessel disease producing spasm. Although not at the origin of the disease, myocarditis is thought to be a superimposed phenomenon and certain mutations may increase the susceptibility to it in ARVD/C.

Three stages have been described in the natural history of ARVD/C. In the initial ‘concealed stage’, individuals are asymptomatic. There are no or subtle structural changes in the right ventricle. The risk of cardiac arrest occurring in the concealed phase is extremely small but not zero. About 60% of the cardiac arrest victims were asymptomatic before their event. As the disease progresses into the ‘clinically overt stage’, symptoms emerge as ventricular arrhythmias and morphological abnormalities in the right ventricle appear. Ventricular arrhythmias range from premature ventricular complexes, non-sustained or sustained ventricular tachycardia, and ventricular fibrillation (Figure 1). Atrial arrhythmias and atrial fibrillation have also been associated with ARVD/C. Haemodynamically tolerated ventricular tachycardia has been found in up to 60% of the index patients in their initial presentation. In a subset of patients, the disease may progress to right, left, or biventricular failure. We recently reported that 49% of ARVD/C patients had at least one heart failure symptom, with exertional dyspnoea being more common than volume overload. Among ARVD/C patients with heart failure, approximately 80% have isolated right ventricular dysfunction. Female sex and lateral precordial T-wave inversions have been associated with heart failure. According to experience at Johns Hopkins and the Nordic ARVD/C Registry, heart failure is the most common (90%) indication to heart transplant in ARVD/C and age at first symptoms under 35 years predicts transplantation. Among patients undergoing heart transplant, 58% had biventricular failure, 29% had right ventricular failure, and 3% had left ventricular failure. Sudden cardiac death also occurs at the end of the disease from overt heart failure.

Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy

2010 Task Force Criteria

Arrhythmogenic right ventricular dysplasia/cardiomyopathy is a clinical diagnosis with no single gold-standard test. The 2010 Task Force Criteria (TFC) is the standard for diagnosis today (Table 2). It is a scoring system combining the six categories of disease features: right ventricular structural alteration, tissue characterization, repolarization abnormalities, depolarization abnormalities, arrhythmias, and family history. In each category, a major, minor, or no criterion can be met. Definite ARVD/C is diagnosed if an individual has at least ‘four points’ with a major criterion worth two points and one minor worth one point. A score of ‘three points’ is classified as probable ARVD/C. The criteria must come from different categories. The 2010 TFC is revised from the 1994 international task force guideline with the addition of quantitative criteria of structural alterations and genetic testing. Its application has reduced the number of individuals satisfying the imaging criterion, increased the number of family
Table 2 2010 Task Force Criteria diagnostic criteria for ARVD/C

| Major | Minor |
|-------|-------|
| **I. Global/regional dysfunction/structural alterations** |  |
| By 2D echo |  |
| Regional RV akinesis, dyskinesia, or aneurysm |  |
| And one of the following (end diastole) |  |
| PLAX RVOT $>32$ mm (correct for body size \[\text{PLAX/BSA} \geq 19 \text{ mm}^2\]) |  |
| PSAX RVOT $>36$ mm (correct for body size \[\text{PSAX/BSA} \geq 21 \text{ mm}^2\]) |  |
| Or fractional area change $\leq 33\%$ |  |
| By MRI |  |
| Regional RV akinesis or dyskinesia or dyssynchronous RV contraction |  |
| And one of the following |  |
| Ratio of RV end-diastolic volume to BSA $\geq 110 \text{ mL/m}^2$ (male) or $>100 \text{ mL/m}^2$ (female) |  |
| Or RV ejection fraction $<40\%$ |  |
| **II. Tissue characterization of wall** |  |
| By 2D echo |  |
| Regional RV akinesia, dyskinesia or aneurysm |  |
| And one of the following (end diastole) |  |
| PLAX RVOT $>29$ to $<32$ mm (correct body size \[\text{PLAX/BSA} \geq 16 \text{ to } 19 \text{ mm}^2\]) |  |
| PSAX RVOT $>32$ to $<36$ mm (correct body size \[\text{PSAX/BSA} \geq 18 \text{ to } 21 \text{ mm}^2\]) |  |
| Or fractional area change $>33\%$ to $<40\%$ |  |
| By MRI |  |
| Regional RV akinesis or dyskinesia or dyssynchronous RV contraction |  |
| And one of the following |  |
| Ratio of RVEDV to BSA $>100$ to $<110 \text{ mL/m}^2$ (male) or $>90$ to $<100 \text{ mL/m}^2$ (female) |  |
| Or RV ejection fraction $>40\%$ to $<45\%$ |  |

**III. Repolarization abnormalities**

| Major | Minor |
|-------|-------|
| T-wave inversions ($V_1$, $V_2$, $V_3$) or beyond; $>14$ years; in absence of complete right bundle branch block | T-wave inversions in $V_1$ or $V_2$; $>14$ years; in absence of complete right bundle branch block or in $V_4$, $V_5$, or $V_6$ |
| QRS $\geq 120$ ms | T-wave inversions in $V_1$ to $V_6$; $>14$ years; in presence of complete right bundle branch block |

**IV. Depolarization/conduction abnormalities**

| Major | Minor |
|-------|-------|
| Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of T wave) in right precordial leads ($V_1$ to $V_3$) | Late potentials by SAECG in $>1$ of 3 parameters in absence of QRS duration of $>110$ ms on ECG |
| Filtered QRS duration (IQRS) $>114$ ms | Duration of terminal QRS $<40 \mu V$ (low-amplitude signal duration) $>38$ ms |
| Root mean square voltage of terminal 40 ms $<20 \mu V$ | Terminal activation duration of QRS $>55$ ms measured from nadir of S wave to end of QRS, including $R^\prime$, in $V_4$, $V_5$, or $V_6$ in absence of complete right bundle branch block |

**V. Arrhythmias**

| Major | Minor |
|-------|-------|
| Non-sustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in II, III, and aVF and positive in aVL) | Non-sustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch morphology with inferior axis (positive QRS in II, III, and aVF and negative in aVL) or of unknown axis |
| $>500$ ventricular extrasystoles per 24 h (Holter) |  |

**VI. Family history**

| Major | Minor |
|-------|-------|
| ARVC confirmed in first-degree relative who meets current TFC | Hx of ARVC in first-degree relative in whom not possible or practical to determine if family member meets TFC |
| ARVC confirmed pathologically at autopsy or surgery in first-degree relative | Premature sudden death ($<35$ years) due to suspected ARVC in first-degree relative |
| Pathogenic mutation (associated or probably associated with ARVC) in patient under evaluation | ARVC confirmed pathologically or by current TFC in second-degree relative |

Adapted from Marcus et al.\(^6\) Permission has been obtained for reuse. Definite $= 2$ major OR 1 major + 2 minor/Borderline = 1 major + 1 minor OR 3 minor/Possible = 1 major OR 2 minor.

ARVD/C: arrhythmogenic right ventricular dysplasia/cardiomyopathy; aVF: augmented voltage unipolar left foot lead; aVL: augmented voltage unipolar left arm lead; BSA: body surface area; ECG: electrocardiogram; MRI: magnetic resonance imaging; PLAX: parasternal long-axis view; PSAX: parasternal short-axis view; RV: right ventricle; RVEDV: right ventricular end-diastolic volume; RVOT: right ventricular outflow tract; SAECG: signal-averaged electrocardiogram; TFC: Task Force Criteria.

members being diagnosed, and increased the overall diagnostic yield of ARVD/C compared with its 1994 counterpart.\(^84,85\) Although being the current gold standard, the 2010 TFC do not apply to left-dominant forms,\(^8\) which will likely be included in future revisions.\(^86\)
General diagnostic approach

When ARVD/C is suspected, the initial evaluation should include clinical inquiry about symptoms related to arrhythmia and heart failure, a detailed multi-generation family history, an exercise history, 12-lead ECG, ambulatory Holter monitoring, echocardiography, and cardiac magnetic resonance imaging (CMR). If the diagnosis remains inconclusive after this non-invasive approach, electrophysiological testing can be considered to characterize the arrhythmic substrate and stratify arrhythmic risk. Endomyocardial biopsy is rarely performed because of its invasiveness and poor sensitivity and specificity. Right ventriculography has been largely replaced by the echocardiography and CMR. Genetic testing is indexed for kindred patients with unequivocal phenotype and cascade screening of family members.

Electrocardiography

The standard 12-lead ECG is rarely normal in ARVD/C patients. It provides critical clues of the depolarization and repolarization abnormalities in ARVD/C. T-wave inversion from V1 to V3 in the absence of complete right bundle branch block is a major TFC criterion and the most common ECG finding (Figure 2). T-wave inversion in V1 and V2 is a minor criterion. Negative T waves may extend to V5 and V6, indicating severe structural abnormality and left-sided involvement. Incomplete right bundle branch block is seen in 15% of ARVD/C patients and T-wave inversions through V3 maintains optimal sensitivity and specificity in its presence. In the presence of complete right bundle branch block, the most sensitive and specific diagnostic parameter is an r/s ratio <1. It is important to recognize that the left dominant form of ARVD/C has a different ECG pattern than the more common right dominant form. Inverted T-waves can be confined to the (infero) lateral leads in left dominant form of ARVD/C. Low precordial QRS voltage may be seen but are not included in the TFC. It can appear in advanced stage of the disease and particularly in PLN mutation carriers.

Epsilon waves are small amplitude deflections after the end of QRS but preceding the T wave. While epsilon waves are a major criterion for ARVD/C, we discourage their use when evaluating patients for ARVD/C. This reflects the fact that a recent study has shown very poor inter-reader reproducibility when panel experts were asked to identify Epsilon wave on ECG tracings of leads V1, V2, and V3. Furthermore, this study revealed that epsilon waves do not impact the diagnosis of ARVD/C as they are only seen in patients with severe disease in whom the diagnosis is met on other structural and electrical criteria. In some difficult cases, Epsilon waves may be better observed with Fontaine lead system or an insertable loop recorder. Terminal activation delay, defined as duration from the nadir of S wave to the end of QRS >55 ms, is a minor criterion for depolarization abnormality. Although late potentials detected by signal-averaged electrocardiogram (SAECG) are also listed as a minor criterion for ARVD/C, we have found them to have poor sensitivity and specificity relative to other criteria and have therefore abandoned performing SAECGs when evaluating patients for possible ARVD/C.

Ambulatory Holter monitoring

Ambulatory Holter monitoring captures premature ventricular complex and sustained or non-sustained ventricular tachycardia, both of which are important for diagnosis and follow-up in ARVD/C. The presence of >500 premature ventricular complex per 24 h is a minor TFC criterion while >1000 per 24 h is predictive of ventricular arrhythmia terminated by defibrillators. Ventricular tachycardia of left bundle branch pattern is consistent with ARVD/C diagnosis and its presence is associated with arrhythmic risk. Arrhythmogenic right ventricular dysplasia/cardiomyopathy patients can be followed by Holter annually to assess their risk of arrhythmia. Because electrical abnormalities on Holter monitoring may precede detectable structural changes in ARVD/C, serial ambulatory Holter can be used for follow-up of family members to facilitate early diagnosis.

Echocardiography

Echocardiography is the first line imaging tool when ARVD/C is suspected. Right ventricular wall motion abnormalities, ventricular dilation, and reduced systolic function are included in the 2010 TFC. A RVOT long-axis diastolic dimension >30 mm occurred in 89% of probands and 14% of healthy controls. Echocardiography has been used in clinical follow-up and showed marked variability in the rate of disease progression. However, more views than standard echocardiography are required to diagnose ARVD/C. Quantitative assessment of right ventricular function also requires high expertise but can lead to effective early detection of structural abnormalities or even abnormal right ventricular deformation prior to structural abnormalities.

Cardiac magnetic resonance

Cardiac magnetic resonance is the preferred imaging modality for ARVD/C in experienced centres in the absence of an implantable cardioverter-defibrillator (ICD). It provides comprehensive information on structural, functional, and tissue characterization of the ventricles. As in echocardiography, only wall motion abnormality, ventricular dilation, and systolic dysfunction are included in the 2010 TFC. Microaneurysm is not a criterion due to the concern of over-use of this term leading to false positive diagnoses. Although the presence of late gadolinium enhancement on CMR has been shown to be a diagnostic feature of ARVD/C and correlates with the myocardial fibro-fatty changes, this MRI parameter was not included in the 2010 Diagnostic Criteria. Despite this, we believe that it is diagnostic value, especially those with the biventricular or left dominant forms. Myocardial fat and wall thinning are not diagnostic for ARVD/C either. Nevertheless, tissue characterization on CMR deserves recognition and combining them to the 2010 TFC may improve diagnostic accuracy. The location of wall motion abnormalities was not addressed in the 2010 TFC. Although the right ventricular apex is part of the initial report describing the triangle of dysplasia, it is not typically affected in isolation. Instead, the basal inferior and anterior right ventricle, and the posterolateral left ventricle are commonly affected. Common normal variants mischaracterized as ARVD/C include right ventricular free wall tether, pectus excavatum, and isolated apicalcaudal bulge (Figure 3). It is important to recognize that MR imaging is not the gold standard for diagnosis of ARVD/C but is only one of a number of diagnostic tests that should be considered when evaluating patients for suspected ARVD/C. In healthcare systems where CMR is not easily accessible, echocardiography in experienced hands using multiple views (with or without contract medium or deformation imaging) can still very valuable.
Family history and genetic testing

Arrhythmogenic right ventricular dysplasia/cardiomyopathy is most commonly characterized by autosomal dominant inheritance with reduced penetrance. As a result, a definite diagnosis in first-degree family members is considered as a major criterion, even when no pathological mutation is detected in the family. According to a recent study, one third of first-degree relatives develop ARVD/C with siblings having the highest risk of disease.

Genetic testing has been incorporated into the 2010 TFC. Genetic counselling and genetic testing is recommended for making the diagnosis in probands and as part of cascade screening of family members of probands with mutations. Mutations are detected in approximately 60% of index patients so the absence of mutations does not exclude the diagnosis. Genetic testing is recommended to identify pathologic mutations in probands fulfilling phenotypic criteria and facilitate cascade screening of family members. The population prevalence of ARVD/C related mutations is unclear. A recent population-based study showed no phenotype in cases with definite loss of function desmosomal variants. Therefore, genetic testing is not recommended in individuals with only one minor 2010 TFC criterion and may be considered when one major or two minor criteria being meet. Given the complexity in result interpretation and the rapid-evolving nature of genetics in ARVD/C, genetic counselling is strongly advised for patients and family members.

Endomyocardial biopsy

The tissue characterization criteria in 2010 TFC focused on the severity of myocyte loss and specified the quantitative parameters of fibrosis. However, endomyocardial biopsy is invasive and its diagnostic sensitivity may be limited due to the patchy distribution of the disease. Although the right ventricular free wall is often affected, biopsy is usually taken from the septum for fear of perforation, which further limits its sensitivity. Immunohistochemical analysis of desmosomal protein localization is not specific for ARVD/C because similar disease patterns can also be seen in sarcoidosis and giant cell myocarditis. Today, endomyocardial biopsy is rarely performed. Its diagnostic value in ARVD/C is mainly for excluding other cardiomyopathies, myocarditis, and sarcoidosis.

Isoproterenol testing

Due to the high prevalence of catecholamine-facilitated ventricular tachycardia in ARVD/C, ventricular arrhythmogenicity during isoproterenol testing has been proposed to assist diagnosis. In the article by Denis et al., isoproterenol is infused continuously for 3 min at 45 μg/min. The test is considered positive if polymorphic premature ventricular contractions with at least 1 couplet or ventricular tachycardia of left bundle branch pattern but excluding RVOT origin is induced. Its sensitivity, specificity, positive, and negative predictive values to diagnose ARVD/C are 91.4%, 88.9%, 43.2%, and 99.1%, respectively. Although it is not included the 2010 TFC, its high sensitivity may help improve diagnosis in early disease stage. The high dose isoproterenol challenge is also being evaluated as a risk predictor in ARVD/C.

Differential diagnosis

The common differential diagnoses for ARVD/C are idiopathic ventricular tachycardia and sarcoidosis. Other conditions to consider include dilated cardiomyopathy, pulmonary hypertension, and Uhl’s disease.

Idiopathic ventricular tachycardia, either from RVOT or aortic sinus cusp, is usually associated with normal ECG and echocardiogram. A scoring system combining T-wave inversions in V1–V3, QRS duration in lead I > 120 ms, QRS notching, and late precordial transition effectively distinguish idiopathic RVOT ventricular tachycardia from ARVD/C. Ectopic QRS morphology (intrinsicoid deflection time > 80 ms, QS pattern in lead V1, and QRS axis > 90°) has been reported recently to aid in differentiating idiopathic RVOT ventricular tachycardia from early...
Management of arrhythmogenic right ventricular dysplasia/cardio-myopathy

The clinical management of ARVD/C patients consists of six aspects: (i) establishing an accurate diagnosis; (ii) risk stratification for sudden death; (iii) prevention of sustained ventricular arrhythmia; (iv) prevention of development of heart failure; (v) cardiac transplant; and (vi) screening and follow-up of family members. We will discuss each of this six-pronged approach here.

Establishing an accurate diagnosis

An accurate diagnosis is the premise of management. As above, lack of awareness of 2010 TFC and misinterpretation of CMR are the most common reasons for misdiagnosis.

Risk stratification for sudden death and decision for an implantable cardioverter-defibrillator

The prognosis of ARVD/C is predominantly related to ventricular arrhythmia which may lead to sudden death. Its estimated overall mortality varies from 0.08% per year to 3.6% per year. Although not tested in randomized controlled trials, the efficacy of ICD therapy has been established by multiple observational studies. Between 40% and 78% of patients received appropriate ICD interventions after implantation. The survival benefit was estimated at 26%. However, the benefit comes at the expense of device/lead-related complications (3.7% per year) and inappropriate ICD interventions (4.4% per year). Therefore, assessing sudden death risk is central in the disease management.

Commonly recognized predictors of life-threatening arrhythmia are summarized here. The strongest predictors are prior cardiac arrest from ventricular fibrillation and sustained ventricular tachycardia. Other major risk factors include arrhythmogenic syncope, nonsustained ventricular tachycardia, and severe systolic dysfunctions of the right, left, or both ventricles. Premature ventricular complex count >1000 per day, T-wave inversion more than three leads, male sex, younger age at presentation, and proband status are minor risk factors. Inducibility at electrophysiology study has been associated with ventricular arrhythmia treated by ICD from the Johns Hopkins and the Zurich experience but not in other studies.

Atrial fibrillation may reflect electrical instability and has been associated with life-threatening arrhythmic events. Risk of ventricular arrhythmia does not seem to significantly increase during pregnancy. Unwillingness to restrict exercise has also been associated with higher risk of ventricular arrhythmia. The absence of risk factors confers a low risk of sudden death (<1% per year) and ICD is not indicated.

Based on the reported risk factors and estimated probability of life-threatening arrhythmic event, the International Task Force Consensus Statement on treatment of ARVD/C grouped patients in to high (>10% per year), intermediate (1–10% per year), or low risk categories (<1% per year). The use of the risk-benefit discussion with patients and family about whether the recommendation of an ICD is appropriate. Another critical variable is a specific
patient’s preferences and values. Whereas some patients are unwilling to accept even a small risk of sudden death and consider placement of an ICD to be reassuring, other patients are adamantly against having an ICD implanted and are willing to accept a small risk of sudden death.

Single-chamber ICDs are recommended to minimize the risk of long-term lead-related complications especially in young patients. Although the number of inappropriate interventions may be decreased by a dual-chamber detection system, the additional lead predisposes to a higher risk of short and long term complications and should be only be employed in the setting of symptomatic bradycardia or AV block (which is virtually never seen in patients with ARVD/C). Anti-tachycardia pacing is highly successful in terminating ventricular arrhythmia and should be programmed in all devices. The role of subcutaneous ICD is under investigation.

Prevention of sustained ventricular arrhythmias

Pharmacologic therapy is commonly utilized in the management of ARVD/C despite the lack of randomized clinical trials. Beta-blockers are recommended as the first line therapy for all definite ARVD/C patients. This recommendation is an extrapolation of the beta-blockers’ efficacy in sudden death prevention in heart failure. It also relies on the observations that ventricular arrhythmia in ARVD/C is often effort-related and catecholamine-facilitated.

The use of anti-arrhythmic drugs rarely eliminates the risk of sudden death and is mainly to reduce the arrhythmia burden. If beta-blocker is ineffective, the conventional ‘wisdom’ is to try sotalol followed by amiodarone. However, evidence from cases series regarding the efficacy of sotalol and amiodarone have been conflicting. The addition of flecainide to beta-blockers may be effective according to a recent case series.

Overall, the use of anti-arrhythmic drugs is empirical. The field is awaiting well-designed clinical trials to guide the use of anti-arrhythmic drugs in ARVD/C management.

Catheter ablation is reserved for ARVD/C patients who fail pharmacologic therapies and continue to have frequent sustained or symptomatic non-sustained ventricular arrhythmias. According to the 2015 Treatment Consensus, ARVD/C patients with incessant ventricular tachycardia (VT) or frequent ICD interventions on VT despite maximal pharmacological therapy should be referred for catheter ablation (Class I indication). Despite a high short-term success rate, the major limitation of catheter ablation is the recurrence of sustained ventricular arrhythmias in 50-70% of patients’ after 3–5 years of follow-up. Epicardial VT ablation or a combined endo-epi approach has been associated with improved short and long term efficacy with a 30% recurrence rate at 2 years of follow up. New arrhythmogenic foci created by the progression of fibro-fatty production may explain the not insignificant recurrence rate. Nevertheless, catheter ablation is still an important palliative procedure to improve patients’ quality life by reducing the arrhythmia burden. Bilateral sympathectomy may be considered for refractory ventricular arrhythmias.

Exercise restriction is recommended to all affected patients and desmosomal mutation carriers. This is because that exercise has been associated with development and severity of the ARVD/C phenotype both in animal and human studies (Figure 5).

Importantly, continuing to participate in competitive sports after diagnosis was associated with higher risk of ventricular tachyarrhythmia in definite and borderline ARVD/C probands. Desmosomal mutation carriers who remained in the top quartile of exercise duration after presentation had the higher risk of incident ventricular arrhythmia.

Prevention of progression and development of heart failure

Few studies have examined structural progression in ARVD/C. It has been shown that structural dysfunction of the disease is progressive but with substantial interpatient variability. As noted above, exercise restriction is believed to slow the disease progression. Because of the proven efficacy of angiotensin-converting enzyme inhibitors in heart failure, it has also been used for most patients with ARVD/C especially in the presence of structural changes.

Cardiac transplantation

Heart transplant is rarely needed in ARVD/C and is the last resort in case of either end-stage heart failure or debilitating lethal arrhythmia. Patients requiring transplant often have disease onset at a younger age. Cardiac transplantation, when needed, is generally performed 10–20 years after initial presentation. Overall, the survival of patients with ARVD/C at 1, 5, and 10 years is 87%, 81%, and 77%, similar to non-ARVD/C recipients and better than ischaemic cardiomyopathy.

Screening approach to family members

After a proband is diagnosed with ARVD/C, there are three scenarios applicable to family members: (i) presence of a pathological mutation; (ii) absence of a pathological mutation, and (iii) presence of a variant of uncertain significance. In the presence of a pathological mutation, mutation-specific ‘cascade’ genetic testing is recommended to identify mutation-carrying family members. Non-carriers are unlikely to develop the disease. For family members with disease-causing mutations, serial examination at one to three year intervals starting at the age of 10 years and exercise restriction are recommended. This serial screening should consist of an ECG, a Holter, and a CMR or echocardiogram. In the absence of a pathological mutation, ARVD/C is still considered hereditary and all family members are recommended to undergo diagnostic testing at 1–3 years intervals. When a variant of uncertain significance is identified, phenotyping of all at-risk relatives remains important and cascade genetic screening should not be performed to assist in clinical management (although it may assist in refinement of variant classification). Again, genetic counselling is strongly recommended in the management of ARVD/C.

Direction for future research

Over the past three decades, much has been learned about diagnosis and treatment of ARVD/C. The complexity of the disease and advance in technology create tremendous opportunities to advance the care we deliver to these patients. Better delineation of the disease progression will deepen the understanding of its natural history and facilitate early diagnosis. As data interpretation catches up with the explosion of sequencing technology, we will have a better insight into its genetic aspect. Detailed and objective measurement of
**Figure 4** A flow chart of risk stratification and indications to ICD implantation in ARVD/C. From Corrado et al. ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; ICD, implantable cardioverter-defibrillator; LV, left ventricle; RV, right ventricle; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.

**Figure 5** Likelihood of ARVD/C diagnosis is associated with exercise history. Likelihood of meeting diagnostic criteria at last follow-up is associated with increasing hours per year of exercise ($P < 0.001$) and participation in endurance athletics ($P < 0.001$). TFC = 2010 Task Force Criteria. From James et al. ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; TFC, Task Force Criteria. Reprinted with permission.
exercise exposure with prospective follow-up will make the personalized recommendation on exercise restriction possible. The refinement of risk stratification for sudden death will enable clinicians to implant an ICD in the right patients. Basic mechanistic research is needed in the search of curative therapy for the disease. At the end of the day, promising therapies will need to be tested in randomized controlled trials. Because ARVD/C is a rare disease, institutional and international collaboration will be required for these exciting endeavours.

Funding
This work was supported by the 2017 Clinical Research Award in Honor of Mark Josephson and Hein Wellens Scholarship from the Heart Rhythm Society (to W.W.). The authors wish to acknowledge funding from the Dr. Francis P. Chiaramonte Private Foundation, the St. Jude Medical Foundation, and Boston Scientific Corp., and the Leducq foundation—RHYTHM Network (all to H.C.). The Johns Hopkins ARVD/C Program is supported by the Leyla Erkan Family Fund for ARVD Research, the Dr. Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family Fund, the Peter French Memorial Foundation, and the Wilmerding Endowments. H.C. receives research funding from Foundation Leducq (16 CVD 02).

Conflict of interest: none declared.

References
1. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J 2015;36:3227–37.
2. Marcus FI, Zareba W, Calkins H, Towbin JA, Basso C, Bluemke DA et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710–20.
3. Mayosi BM, Fish M, Shaboodien G, Mastantuono E, Kraus S, Wieland T et al. Mutations in desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004;36:1162–4.
4. Agullo-Pascual E, James CA, Leo-Macias A, Cerrone M, Zhang Te Riele ASJM. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Cardiovasc Res 2017;113:102–11.
5. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA et al. Mutations in the desmosomal protein plakoglobin-2 are associated with non-canonical mechanisms for disease pathogenesis. Cardiovasc Res 2000;47:2774–85.
6. Pilotou K, Nava A, Basso C, Beffagna G, Baecke J, Lorenzon A et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:1171.
7. Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 2006;79:978–84.
8. Tinesten JP, Van Gelder IC, Asimaki A, Suurmeyer AJH, Wiesfeld AC, Jongbloed JDH et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm 2009;6:1574–83.
9. Te Riele ASJM, Agullo-Pascual E, James CA, Leo-Macias A, Cerrone M, Zhang M et al. Multilevel analyses of CSN5 mutations in arrhythmogenic right ventricular cardiomyopathy. Circulation 2009;119:102–11.
10. Young SG, Jung HJ, Lee JM, Fong LG. Nuclear laminas and neurobiology. Mol Cell Biol 2014;34:2776–85.
11. Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 2011;124:876–85.
12. Rijpma IAW, van Zwag PA, van der Groeneweg JA, Nannenberg EA, Jongbloed JDH, Zwinderman AH et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 2014;7:455–65.
13. Ortiz-Gengs MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Arenda R, Climenti V et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440–51.
14. Hengel J, van Calore M, Baecke J, Dazzo E, Mazzotti E, De Bortoli M et al. Mutations in the area composita protein aT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013;34:201–10.
15. Mayosi BM, Fish M, Shaboodien G, Mastantuono E, Kraus S, Wieland T et al. Identification of caderin 2 (CDH2) mutations in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2017;10:e001605.
16. Befagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C et al. Regulatory mutations in transforming growth factor-beta2 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 2005;65:366–73.
17. Lazzarini E, Jongbloed JDH, Pilotou K, Thieme G, Basso C, Birkker H et al. The ARVD/C genetic variants database. 2014 update. Hum Mutat 2015;36:403–10.
Diagnostic and therapeutic strategies for ARVD/C

36. Hoornjte ET, Te Rijdt WP, James CA, Pilocou K, Basso C, Judge DP et al. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovases Res 2017;113:1521–31.

37. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JDH et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:885–93.

38. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilocou K, Mazzotti E et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6:33–42.

39. Lopez-Ayala JM, Pastor-Qurante F, Gonzalez-Carrillo J, Lopez-Cueva D, Sanchez-Munoz J, Oliva-Sandoval MJ et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm 2015;12:766–73.

40. Merer ND, Hodgkinson KA, Haywood AFM, Connors S, French VM, Drendshak J-D et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, J-I arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008;82:809–21.

41. Zwaag PA, van der Jongbloed JDH, Berg MP, van den Smagt JJ, van der Heijden F et al. Disproportionate exercise load and remodeling of the Athlete’s right ventricle. Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. Eur Heart J 2006;27:1847–54.

42. La Gerche A, Heidbuchel H, Burns AT, Mooney DJ, Taylor AJ, Pfluger HB et al. Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells in arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2013;124:974–81.

43. Corrado D, Basso C, Judge DP. Arrhythmogenic right ventricular cardiomyopathy. Circ Res 2017;121:784–80.

44. Melino B, Domenichelli A, Canestrelli C, Bassi P, Ascierto PA et al. Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy. JCI Insight 2017;2:e95923.

45. García-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury S et al. Chelko SP, Asimaki A, Andersen P, Bedja D, Amat-Alarcon N, DeMazumder D et al. Is the Brugada syndrome a distinct clinical entity? J Cardiovasc Electrophysiol 2019;30:332–6.

46. Ghinami E, Basso C, Barsevick AM, Rizzo G, Vinciarelli A, Tandri H et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:2540–50.

47. Bhonsale A, James CA, Tichnell C, Murray B, Russell SD et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc 2014;3:e001471.

48. Corrado D, Basso C, Rizzoli G, Schiavon M, Thienn G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:1959–63.

49. Corrado D, Basso C, Pave A, Michei P, Schiavon M, Thienn G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:1593–601.

50. Mazzanti A, Ng K, Faragil A, Maragna R, Chiadorari E, Orphanou N et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:2540–50.

51. Basso C, Corrado D, Garcia-Prieto J, Garcia-Ruiz JM, Ruiz-Moreno J et al. Cardiovascular death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2017;69:1438–50.

52. Kirkhoff P, Fabritz L, Zwiener M, Witt H, Schäfers M, Zellerhoff S et al. Age and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006;114:1678–86.

53. Rovai A-C, Marcus F, Estes NAM, Link M, Mcnitt S, Polonsky B et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013;36:1735–43.

54. Sawant AC, Bhonsale A, Riele ASJ, De Tichnell C, Murray B, Russell SD et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc 2014;3:e001471.

55. Corrado D, Basso C, Rizzoli G, Schiavon M, Thienn G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:1959–63.

56. Mazzanti A, Ng K, Faragil A, Maragna R, Chiadorari E, Orphanou N et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:2540–50.
80. Telford RJ, Cai C, Judge DP, Tichnell C, Murray B, Bhonsale A et al. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2012;59:289–90.
81. Gilljam T, Haugaa KH, Jensen HK, Svensson A, Bundgaard H, Hansen J et al. Heart transplantation in arrhythmogenic right ventricular cardiomyopathy—Experience from the Nordic ARVC registry. Int J Cardiol 2018;250:201–6.
82. Marcus FI, McKenna WJ, Serrulli D, Basso C, Baus B, Bluemke DA et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533–41.
83. McKenna WJ, Thieme G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Heart 1994;71:215–8.
84. Femia G, Sy RW, Puranik R. Systematic review: impact of the new task force criteria in the diagnosis of arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2017;241:311–7.
85. Cox MG, vanderSmagt Jj, Noorman M, Wiesfeld AC, Volders PG, vanLangen IM et al. ARVD/C diagnosis impact of new task force criteria. Circ Arrhythm Electrophysiol 2010;3:126–33.
86. Castaño Gutiérrez SL, Kamel IR, Zimmerman SL. Current concepts on diagnosis and prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Thorac Imaging 2016;31:324–35.
87. Tanawuttiwat T, Te Riele ASJM, Philips B, James CA, Murray B, Tichnell C et al. Electroanatomic correlates of depolarization abnormalities in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol 2016;27:443–52.
88. Tandri H, Asimaki A, Abraham T, Dalal D, Tops L, Jain R et al. Prolonged RV epicardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2009;6:769–75.
89. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009;302:2471–6.
90. Riele ASJM, Te James CA, Bhonsale A, Groeneweg JA, van der Rijsingen IAW, van Asimaki A, Jongbloed JDH, Veldhuisen JDH et al. Arrhythmogenic right ventricular cardiomyopathy associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761–9.
91. Yoerger DM, Marcus F, Serrulli D, Calkins H, Towbin JA, Zareba W et al. Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol 2005;45:60–5.
92. Zorzi A, Migliore F, Elmaghawry M, Silvano M, Marra MP, Niero A et al. Incremental value of cardiac magnetic resonance imaging in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:293–302.
93. Sagner AM, Vecchati A, Baldinger SH, Rüegs S, Mederios-Domingo A, Mueller-Burri AS et al. Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ Cardiovasc Imaging 2014;7:527–33.
94. Leren IS, Sørensrn I, Hafstad T, Edvardsen T, Haugaa KH. Combnation of ECG and echocardiography for identification of arrhythmic events in early ARVC. JACC Cardiovasc Imaging 2017;10:503–13.
95. Mast TP, James CA, Calkins H, Teske A, Tichnell C, Murray B et al. Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy. JAMA Cardiovasc Imaging 2016;10:1957–65.
96. Yoon HJ, Park SM, Kim JH, Song B, Youn CK, Seo WH et al. Clinical presentation of early arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2017;120:2061–6.
97. Zwaag PA, van der Rijsingen IAW, van Asimaki A, Jongbloed JDH, Veldhuisen JDH et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: impact of new task force criteria. JACC Cardiovasc Imaging 2014;7:1084–90.
98. Tandri H, Asimaki A, Abraham T, Dalal D, Tops L, Jain R et al. Prolonged RV epicardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2009;6:769–75.
99. Hurst JW. Naming of the waves in the ECG, with a brief account of their genetic basis. Circulation 1998;99:1937–42.
100. Fontaine GH, Duthoit G, Li G, Andreolletti L, Gandjbakhch E, Frank R. Epsilon wave on an electronic loop in a case of arrhythmogenic right ventricular dysplasia with myocarditis: an updated definition of the Epsilon Wave. Europace 2017;19:384–90.
101. Cox MG, Nelen MR, Wilde AA, Wiesfeld AC, van der Smagt Jj, Loh P et al. Activation delay and VT parameters in arrhythmogenic right ventricular dysplasia/cardiomyopathy: toward improvement of diagnostic ECG criteria. J Cardiovasc Electrophysiol 2008;19:775–81.
121. Denis A, Sacher F, Deval N, Lim HS, Cochet H, Shah AJ et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 2014;7:590–7.

122. Indik JH, Dallas WJ, Ovitt T, Wichter T, Marcus FI. Do patients with right ventricular outflow tract ventricular arrhythmias have a normal right ventricular wall motion? A quantitative analysis compared to normal subjects. Cardiology 2005;104:10–1.

123. Hofffmaer KS, Bhave PD, Marcus GM, James CA, Tichnell C, Chopra N et al. An electrocardiographic scoring system for distinguishing right ventricular outflow tract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia. Heart Rhythm 2013;10:477–82.

124. Novak J, Zorzi A, Castelletti S, Pantasis A, Rigato I, Corrado D et al. Electrocardiographic differentiation of idiopathic right ventricular outflow tract ectopy from early arrhythmogenic right ventricular cardiomyopathy. Europace 2017;19:622–8.

125. Philips B, Madhavan S, James CA, Riele ASJM, Te Murray B, Dalal D et al. Arrhythmogenic right ventricular dysplasia/cardio-myopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 2014;7:230–6.

126. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411–21.

127. Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet 1994;3:959–62.

128. Corrado D, Leoni L, Link MS, Bella PD, Gaita F, Curnis A et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108:3084–91.

129. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122:1144–52.

130. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James CA et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardio-myopathy: a report from the North American ARVC registry. J Am Coll Cardiol 2009;54:609–15.

131. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2017;14:564–9.

132. Philips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardio-myopathy. Circ Arrhythm Electrophysiol 2012;5:499–505.

133. Verma A, Kilicaslan F, Schweikert RA, Tomassoni G, Rossillo A, Marrouche NF et al. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation 2005;111:3209–16.

134. Miljepen H, State S, Chillou C, de Magnin-Poull I, Dotto P, Andronache M et al. Electroanatomic mapping characteristics of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Europace 2005;7:516–24.

135. Riele ASJM, Te, Ajijola OA, Shikummar K, Tandri H. Role of bilateral sympathectomy in the treatment of refractory ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardio-myopathy. J Am Coll Cardiol 2004;43:1843–2.

136. Saberi N, Hasselberg NE, Borgquist R, Platovoy PG, Sarvari SI, Smith HJ et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail 2014;16:1337–44.

137. DePasquale EC, Cheng RK, Deng MC, Nsair A, McKenna WJ, Fonarow GC et al. Survival after heart transplantation in patients with arrhythmogenic right ventricular cardiomyopathy. J Card Fail 2017;23:107–12.